Grasp the latest information from Olin and understand the new trends in the industry.
On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in
On December 11, 2025, Mr. Matthew Fosbery, Deputy Commercial Consul of Australia in Chengdu and Trade & Investment Commissioner of Austrade, and Ms. Wang Ming, Commercial Officer of Austrade, visited Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, stock code: 688319) for inspection and exchanges, and had in-
On November 21, 2025, the Phase IIIa clinical trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) jointly developed by Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) and its subsidiaries Chengdu XinNuoming Biotechnology Co., Ltd. and Lanzhou Bailing Biotechnology Co., Ltd. successfully completed the enrollment of all subjects, marking a key progress of this project in the clinical research stage and a solid step forward for the final market approval of
On November 14, 2025, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, stock code: 688319) officially received the audit result notice from the Food and Drug Administration (FDA) of the Philippines. In the comprehensive on-
From October 28 to 30, 2025, CPHI Worldwide Europe 2025, the world’s largest and most influential professional event in the pharmaceutical industry, was grandly held at Messe Frankfurt, Germany. This exhibition attracted 2,000 exhibitors and 62,000 professional visitors from more than 130 countries. As a top industry event held for 35 consecutive years, CPHI Worldwide Europe 2025 gathered top enterprises, decision-
Recently, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) successfully held the Kick-off Meeting & Investigator Training for Phase IIIa Clinical Trials of Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) in Weiyuan County, Neijiang City, Sichuan Province and Jiangjin District, Chongqing Municipality.
On September 28, the Chengdu Industrial Boutique Release & Supply-Demand Matching Conference with the theme of “Supply-Demand Collaboration, Co-creating Boutiques” was grandly held in Chengdu. The Haemophilus influenzae type b conjugate vaccine (Hib vaccine) of Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was honorably selected and successfully included in the new list of “Chengdu Industrial Boutiques”.